Who are Cyklokapron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trasylol, Cyklokapron, Amicar, Tranexamic Acid plus standard of care, Tranexamic Acid (IV), Topical tranexamic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cyklokapron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Cyklokapron — Competitive Intelligence Brief

Cyklokapron (Tranexamic Acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic agent. Area: Rare Disease.

marketed Antifibrinolytic agent Plasminogen lysine binding sites; fibrin Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Cyklokapron (Tranexamic Acid) — Pfizer Inc.. Tranexamic acid occupies lysine receptor binding sites on plasmin, preventing fibrin dissolution.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cyklokapron TARGET	Tranexamic Acid	Pfizer Inc.	marketed	Antifibrinolytic agent	Plasminogen lysine binding sites; fibrin
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid plus standard of care	Tranexamic Acid plus standard of care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid (IV)	Tranexamic Acid (IV)	Samsung Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Topical tranexamic acid	Topical tranexamic acid	Aswan University Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic agent class)

Montefiore Medical Center · 2 drugs in this class
Pfizer · 2 drugs in this class
Hamilton Health Sciences Corporation · 2 drugs in this class
Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
NYU Langone Health · 1 drug in this class
Mount Sinai Hospital, Canada · 1 drug in this class
Dr. Lutfi Kirdar Kartal Training and Research Hospital · 1 drug in this class
Carlos A Acosta-Olivo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cyklokapron — Competitive Intelligence Brief. https://druglandscape.com/ci/cyklokapron. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab